Adnan Farooqui

What a drastically dramatic, chaotic, hectic and rather irritating two days it has been. Its a story of confused, infatuated university students, who seek my advise in matters relating to their hearts.

So what exactly is the story here?

BOSTON - Cancer patients, brace yourselves. Many new drug treatments cost nearly $100,000 a year, sparking fresh debate about how much a few months more of life is worth.

The latest is Provenge, a first-of-a-kind therapy approved in April. It costs $93,000 and adds four months' survival, on average, for men with incurable prostate tumors. Bob Svensson is honest about why he got it: insurance paid.

"I would not spend that money," because the benefit doesn't seem worth it, says Svensson, 80, a former corporate finance officer from Bedford, Mass.